文献速递肿瘤 PET/CT骨显像与常规 SPECT

68Ga-PSMA PET/CT检出肾细胞癌转移灶:18F-FDG PET/CT漏诊

68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2023-01-01

本文报告一例肾细胞癌(RCC)病例,18F-FDG与68Ga-PSMA PET/CT在肝转移灶均显示摄取增高,但肝下腹膜沉积灶仅在PSMA显像中显示摄取。由于背景摄取较低,PSMA对肝病灶显示更佳,提示68Ga-PSMA可能是RCC评估的潜在示踪剂。

要点

  • RCC肝转移灶在18F-FDG与68Ga-PSMA PET/CT均见摄取增高。
  • 肝下腹膜沉积灶仅在68Ga-PSMA PET/CT显示摄取。
  • PSMA背景摄取较低,肝病灶显示优于FDG,提示其可能用于RCC评估。

核心结论

  • 68Ga-PSMA PET/CT在肝下腹膜沉积灶检出方面优于18F-FDG PET/CT,且因背景摄取较低对肝病灶显示更佳,提示68Ga-PSMA可能是RCC评估的潜在示踪剂。

研究设计与样本

  • 本文为病例报告,报告一例肾细胞癌(RCC)患者行18F-FDG与68Ga-PSMA PET/CT显像。

主要发现

  • 18F-FDG与68Ga-PSMA PET/CT在肝转移灶均显示摄取增高。
  • 肝下腹膜沉积灶仅在68Ga-PSMA PET/CT显示摄取。
  • 因背景摄取较低,肝病灶在68Ga-PSMA PET/CT显示更佳。

临床怎么用

  • 原文结论提示68Ga-PSMA可能是RCC评估的潜在示踪剂,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal cell carcinoma (RCC) accounts for ~2% of global cancers and deaths. Survival depends on initial staging and shows poor survival rate in metastatic disease. CT and MRI are used for evaluating RCC, and PET/CT is used for metastatic disease assessment. We report a case of RCC, where both 18F-FDG and 68Ga-PSMA PET/CT showed increased uptake in liver metastatic lesions; however, a subhepatic peritoneal deposit showed uptake only in PSMA. Also, liver lesions were seen better in PSMA owing to lesser background uptake, suggesting a possibility of 68Ga-PSMA being a potential tracer for RCC evaluation.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jha S, Hemrom A, Shamim SA, et al. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT. Clin Nucl Med. 2023. PMID: 37133514. doi:10.1097/RLU.0000000000004648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。